The Therapeutic Goods Administration (TGA) has approved new autoinjectors for the emergency treatment of anaphylaxis.
Anaphylaxis is a severe and potentially life-threatening allergic reaction that develops rapidly in response to allergen exposure and should always be treated as a medical emergency.
Anapen 300®, Anapen 500®, and Anapen 150 Junior® (Anapen Junior) adrenaline (epinephrine) autoinjectors have been listed on the ARTG for the emergency treatment of anaphylaxis. Australians weighing 60kg and over living with anaphylaxis can now access a 500-mcg adrenaline autoinjector dose.
The Anapen auto-injector is intended for immediate self-administration by an individual with a history of anaphylaxis and is designed to deliver a single, intramuscular dose of 150/300/500 micrograms of adrenaline (epinephrine) to the outer-mid thigh and has a shelf life of up to 24 months.
Although EpiPens and the new Anapen autoinjectors appear superficially similar, they have substantially different administration techniques. The autoinjector is triggered by pushing a red button with the thumb. Device training and education are strongly recommended for patients and carers.
It is expected that the new Anapen autoinjectors will be listed on the PBS in September 2021, according to the Australasian Society of Clinical Immunology and Allergy (ASCIA).
For information on device training, visit our page on Anaphylaxis training.